173 related articles for article (PubMed ID: 23083502)
41. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
42. Chronological Trends of Breast Ductal Carcinoma In Situ: Clinical, Radiologic, and Pathologic Perspectives.
Lee SE; Kim HY; Yoon JH; Kim EK; Kim JY; Kim MJ; Kim GR; Park YV; Moon HJ
Ann Surg Oncol; 2021 Dec; 28(13):8699-8709. PubMed ID: 34196861
[TBL] [Abstract][Full Text] [Related]
43. Ductal carcinoma in situ of the breast in Singapore: recent trends and clinical implications.
Tan KB; Lee HY; Putti TC
ANZ J Surg; 2002 Nov; 72(11):793-7. PubMed ID: 12437689
[TBL] [Abstract][Full Text] [Related]
44. Screening-detected calcified and non-calcified ductal carcinoma in situ: differences in the imaging and histopathological features.
Mun HS; Shin HJ; Kim HH; Cha JH; Kim H
Clin Radiol; 2013 Jan; 68(1):e27-35. PubMed ID: 23177096
[TBL] [Abstract][Full Text] [Related]
45. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
46. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.
Wang SY; Long JB; Killelea BK; Evans SB; Roberts KB; Silber A; Gross CP
Breast Cancer Res Treat; 2016 Jul; 158(1):139-148. PubMed ID: 27287780
[TBL] [Abstract][Full Text] [Related]
47. Histopathological characteristics of breast ductal carcinoma in situ and association with imaging findings.
Tang X; Yamashita T; Hara M; Kumaki N; Tokuda Y; Masuda S
Breast Cancer; 2016 May; 23(3):491-8. PubMed ID: 25644245
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.
Rauch GM; Kuerer HM; Scoggins ME; Fox PS; Benveniste AP; Park YM; Lari SA; Hobbs BP; Adrada BE; Krishnamurthy S; Yang WT
Breast Cancer Res Treat; 2013 Jun; 139(3):639-47. PubMed ID: 23774990
[TBL] [Abstract][Full Text] [Related]
49. Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation.
Vernet-Tomas M; Mojal S; Gamero R; Nicolau P; Rodríguez-Arana A; Plancarte F; Corominas JM; Serrano-Munne L; Carreras R; Sabadell D
Breast Cancer; 2017 May; 24(3):466-472. PubMed ID: 27639877
[TBL] [Abstract][Full Text] [Related]
50. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
51. Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.
Toesca A; Botteri E; Lazzeroni M; Vila J; Manika A; Ballardini B; Bettarini F; Guerrieri-Gonzaga A; Bonanni B; Rotmensz N; Viale G; Veronesi P; Luini A; Veronesi U; Gentilini O
Breast; 2014 Dec; 23(6):829-35. PubMed ID: 25261930
[TBL] [Abstract][Full Text] [Related]
52. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
[TBL] [Abstract][Full Text] [Related]
53. Spectrum of diseases presenting as architectural distortion on mammography: multimodality radiologic imaging with pathologic correlation.
Shaheen R; Schimmelpenninck CA; Stoddart L; Raymond H; Slanetz PJ
Semin Ultrasound CT MR; 2011 Aug; 32(4):351-62. PubMed ID: 21782125
[TBL] [Abstract][Full Text] [Related]
54. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
55. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
56. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
Partridge A; Adloff K; Blood E; Dees EC; Kaelin C; Golshan M; Ligibel J; de Moor JS; Weeks J; Emmons K; Winer E
J Natl Cancer Inst; 2008 Feb; 100(4):243-51. PubMed ID: 18270338
[TBL] [Abstract][Full Text] [Related]
57. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983-2007.
Puig-Vives M; Pollan M; Rue M; Osca-Gelis G; Saez M; Izquierdo A; Marcos-Gragera R
Breast; 2012 Oct; 21(5):646-51. PubMed ID: 22340960
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast.
Jang SM; Sim J; Han H; Ahn HI; Kim H; Yi K; Jun YJ; Rehman A; Chung MS; Jang K; Paik SS
J Clin Pathol; 2013 Aug; 66(8):681-6. PubMed ID: 23559354
[TBL] [Abstract][Full Text] [Related]
59. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
[TBL] [Abstract][Full Text] [Related]
60. Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma.
Lamb LR; Kim G; Oseni TO; Bahl M
Acad Radiol; 2021 Mar; 28(3):e71-e76. PubMed ID: 32222328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
